Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
Rhea-AI Summary
Crinetics Pharmaceuticals (Nasdaq: CRNX) will host a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide a PALSONIFY (paltusotine) commercialization update and to disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia (CAH).
The event includes prepared remarks followed by a live Q&A. A live audio-only webcast will be available and an archived webcast will be posted on the company's Events & Presentations page at www.crinetics.com/events. Dial-in numbers: 1-833-470-1428 (U.S.) or 1-646-844-6383 (international); Access Code: 640078.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CRNX gained 3.10%, reflecting a moderate positive market reaction. Argus tracked a peak move of +20.0% during that session. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $137M to the company's valuation, bringing the market cap to $4.57B at that time. Trading volume was very high at 4.6x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves, with names like IMVT and APLS up while KYMR and VKTX are down, suggesting today’s setup in CRNX is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Conference participation | Neutral | +6.4% | Announcement of J.P. Morgan Healthcare Conference presentation and webcast access. |
| Dec 11 | Phase 3 initiation | Positive | +2.4% | First patient dosed in Phase 3 CALM-CAH trial of atumelnant in adults. |
| Dec 10 | Equity inducement grants | Neutral | +2.6% | Inducement stock options and RSUs granted to new non-executive employees. |
| Dec 03 | Early-stage trial start | Positive | +4.4% | First patient dosed in Phase 1/2 BRAVESST2 trial of CRN09682 in SST2+ tumors. |
| Nov 20 | Phase 3 enrollment | Positive | +2.1% | First patient randomized in pivotal Phase 3 CAREFNDR trial of paltusotine. |
Recent news has usually seen positive price reactions, with one notable divergence on prior positive Phase 2 atumelnant data.
Over the past several months, Crinetics has reported a series of pipeline and corporate milestones. These include Phase 3 initiation for atumelnant in CAH on Dec 11, 2025, new inducement equity grants on Dec 10, 2025, and dosing the first patient in the BRAVESST2 trial of CRN09682 on Dec 3, 2025. Earlier, the CAREFNDR Phase 3 trial of paltusotine in carcinoid syndrome began enrollment on Nov 20, 2025. Today’s planned topline results from the fourth Phase 2 atumelnant cohort build directly on this ongoing clinical development momentum.
Market Pulse Summary
This announcement sets expectations for a business update on PALSONIFY commercialization alongside topline results from the fourth cohort of a Phase 2 atumelnant trial in congenital adrenal hyperplasia. It follows recent milestones across paltusotine, atumelnant, and CRN09682. Key elements to watch include biomarker and symptom data continuity with prior Phase 2 atumelnant results, any commentary on next development steps, and how management frames the broader pipeline strategy during the January 5, 2026 call.
Key Terms
congenital adrenal hyperplasia medical
AI-generated analysis. Not financial advice.
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia.
Conference Call and Webcast Details
Management will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events. To participate, please dial 1-833-470-1428 (domestic) or 1-646-844-6383 (international) and refer to Access Code 640078.
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When is the Crinetics (CRNX) webcast for the PALSONIFY update and atumelnant Phase 2 cohort 4 topline results?
How can investors access the Crinetics (CRNX) live audio-only webcast on January 5, 2026?
Will Crinetics (CRNX) post a replay of the PALSONIFY and atumelnant presentation?
What topics will Crinetics (CRNX) address during the January 5, 2026 call?
Will there be a Q&A during the Crinetics (CRNX) January 5, 2026 event?
